Increased Cancer Risk in Postmenopausal Women with Central Obesity

TON - November 2017, Vol 10, No 6 - Conference Correspondent
Phoebe Starr

Madrid, Spain—Central obesity increases the risk for developing cancer in postmenopausal women more than high body mass index (BMI) and fat percentage, according to a study reported at the 2017 European Society for Medical Oncology Congress.

“The findings put a new spin on weight management priorities for women in this age group, who are prone to abdominal weight gain. BMI and fat percentage may not be adequate measures of cancer risk,” said lead investigator Line Mærsk Staunstrup, MSc, PhD student, Department of Biomedical Sciences, University of Copenhagen, and Research Assistant, Nordic Bioscience A/S and ProScion, Herlev, Denmark.

The Prospective Epidemiological Risk Factor study enrolled 5855 women from 1999 to 2001. Mean age at enrollment was 71 years. Medical history and demographic information were collected, and a dual x-ray absorptiometry scan was performed to measure bone mass, bone-free lean mass, and fat mass.

Data were grouped according to breast and/or ovarian cancer, lung and/or gastrointestinal cancer, and other cancers. Cox proportional hazard regression models examined the association between body fat distribution and risk for cancer, adjusted for standard risk factors that included BMI.

Among 811 solid cancers, 293 breast and/or ovarian, 345 lung and/or gastrointestinal, and 173 other cancers were identified. In the overall study, central obesity was a significant predictor of cancer diagnosis (P <.001). BMI and fat percentage were not associated with cancer risk.

Analysis of the data in specific cancers found that central obesity was a significant risk factor for only lung and gastrointestinal cancer (P <.05).

“This information is useful for elderly women, as the transition to menopause is accompanied by a shift in body fat toward the central trunk area. Clinicians can use this information in conversations with women who are at higher risk of cancer,” Ms Staunstrup said.

Related Items
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
Phoebe Starr
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Prostate Cancer
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
JHOP Web Exclusives published on September 7, 2018 in Emerging Therapies
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
JHOP Web Exclusives published on August 6, 2018 in Immunotherapy
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Last modified: December 8, 2017